CNS Pharmaceuticals Management
Management criteria checks 3/4
CNS Pharmaceuticals' CEO is John Climaco, appointed in Sep 2017, has a tenure of 7.25 years. total yearly compensation is $525.00K, comprised of 100% salary and 0% bonuses, including company stock and options. directly owns 0.021% of the company’s shares, worth $1.35K. The average tenure of the management team and the board of directors is 5.5 years and 2 years respectively.
Key information
John Climaco
Chief executive officer
US$525.0k
Total compensation
| CEO salary percentage | 100.0% |
| CEO tenure | 7.3yrs |
| CEO ownership | 0.02% |
| Management average tenure | 5.5yrs |
| Board average tenure | 2yrs |
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$17m |
| Jun 30 2024 | n/a | n/a | -US$16m |
| Mar 31 2024 | n/a | n/a | -US$17m |
| Dec 31 2023 | US$525k | US$525k | -US$19m |
| Sep 30 2023 | n/a | n/a | -US$19m |
| Jun 30 2023 | n/a | n/a | -US$18m |
| Mar 31 2023 | n/a | n/a | -US$17m |
| Dec 31 2022 | US$828k | US$525k | -US$15m |
| Sep 30 2022 | n/a | n/a | -US$13m |
| Jun 30 2022 | n/a | n/a | -US$14m |
| Mar 31 2022 | n/a | n/a | -US$14m |
| Dec 31 2021 | US$846k | US$525k | -US$14m |
| Sep 30 2021 | n/a | n/a | -US$14m |
| Jun 30 2021 | n/a | n/a | -US$12m |
| Mar 31 2021 | n/a | n/a | -US$11m |
| Dec 31 2020 | US$2m | US$440k | -US$9m |
| Sep 30 2020 | n/a | n/a | -US$9m |
| Jun 30 2020 | n/a | n/a | -US$8m |
| Mar 31 2020 | n/a | n/a | -US$6m |
| Dec 31 2019 | US$1m | US$214k | -US$4m |
| Sep 30 2019 | n/a | n/a | -US$8m |
| Jun 30 2019 | n/a | n/a | -US$7m |
| Mar 31 2019 | n/a | n/a | -US$7m |
| Dec 31 2018 | US$164k | US$150k | -US$7m |
Compensation vs Market: John's total compensation ($USD525.00K) is about average for companies of similar size in the US market ($USD649.63K).
Compensation vs Earnings: John's compensation has been consistent with company performance over the past year.
CEO
John Climaco (55 yo)
7.3yrs
Tenure
US$525,000
Compensation
Mr. John Michael Climaco, Esq., J.D served as Chairman of the Board at CNS Pharmaceuticals, Inc. and joined CNS in September 2017. Mr. Climaco has been the Chief Executive Officer of CNS Pharmaceuticals, I...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 7.3yrs | US$525.00k | 0.021% $ 1.3k | |
| Chief Financial Officer | 5.1yrs | US$401.52k | 0.0091% $ 589.8 | |
| Chief Medical Officer | no data | US$270.15k | 0.00045% $ 29.2 | |
| Founder | no data | no data | no data | |
| Chief Science Officer | 5.5yrs | no data | no data |
5.5yrs
Average Tenure
62yo
Average Age
Experienced Management: CNSP's management team is seasoned and experienced (5.5 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | no data | US$525.00k | 0.021% $ 1.3k | |
| Independent Chairman of Board | 2yrs | US$112.64k | 0.0011% $ 70.8 | |
| Independent Director | 6.5yrs | US$135.46k | 0.0017% $ 110.4 | |
| Independent Director | 1.6yrs | US$58.31k | 0.00055% $ 35.7 | |
| Independent Director | 7.1yrs | US$115.16k | 0.0055% $ 357.3 | |
| Scientific Advisory Board Member | no data | no data | no data | |
| Independent Director | less than a year | no data | 0.00019% $ 12.3 |
2.0yrs
Average Tenure
55yo
Average Age
Experienced Board: CNSP's board of directors are not considered experienced ( 2 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/31 04:58 |
| End of Day Share Price | 2024/12/31 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
CNS Pharmaceuticals, Inc. is covered by 4 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Matthew Cross | Alliance Global Partners |
| Bruce Jackson | Benchmark Company |
| Robert LeBoyer | Ladenburg Thalmann & Company |